Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.